Developing a Raman spectroscopy-based tool to stratify patient response to pre-operative radiotherapy in rectal cancer by Kirkby, CJ et al.
Analyst
PAPER
Cite this: DOI: 10.1039/d0an01803a
Received 8th September 2020,
Accepted 4th November 2020
DOI: 10.1039/d0an01803a
rsc.li/analyst
Developing a Raman spectroscopy-based tool to
stratify patient response to pre-operative
radiotherapy in rectal cancer†
Chloe J. Kirkby, a Julia Gala de Pablo, b,c Emma Tinkler-Hundal,a
Henry M. Wood, a Stephen D. Evansb and Nicholas P. West *a
Rectal cancer patients frequently receive pre-operative radiotherapy (RT), prior to surgical resection.
However, colorectal cancer is heterogeneous and the degree of tumour response to pre-operative RT is
highly variable. There are currently no clinically approved methods of predicting response to RT, and a
significant proportion of patients will show no clinical benefit, despite enduring the side-effects. We eval-
uated the use of Raman spectroscopy (RS), a non-destructive technique able to provide the unique
chemical fingerprint of tissues, as a potential tool to stratify patient response to pre-operative RT. Raman
measurements were obtained from the formalin-fixed, paraffin-embedded (FFPE) pre-treatment biopsy
specimens of 20 rectal cancer patients who received pre-operative RT. A principal component analysis
and linear discriminant analysis algorithm was able to classify patient response to pre-operative RT as
good or poor, with an accuracy of 86.04 ± 0.14% (standard error). Patients with a good response to RT
showed greater contributions from protein-associated peaks, whereas patients who responded poorly
showed greater lipid contributions. These results demonstrate that RS is able to reliably classify tumour
response to pre-operative RT from FFPE biopsies and highlights its potential to guide personalised cancer
patient treatment.
Introduction
Colorectal cancer (CRC) is common, it affects approximately
42000 people in the UK annually, and is the second most
common cause of cancer related death.1 A significant pro-
portion of rectal cancer patients receive pre-operative radio-
therapy (RT), prior to surgical resection. There are three
common RT approaches; short course RT (SCRT), long course
RT (LCRT) and long course chemoradiotherapy (LCCRT).
Treatment varies across the National Health Service (NHS), as
current guidelines from the National Institute for Health and
Care Excellence (NICE) state that in the UK, pre-operative
SCRT or LCCRT can be offered to rectal cancer patients with
operable tumours and a predicted moderate or high risk of
local recurrence.2,3 Pre-operative RT aims to reduce the risk of
local recurrence, as it enables the possibility of tumour
regression prior to surgery, increasing the likelihood of achiev-
ing a complete resection. However, CRC is morphologically
and molecularly heterogeneous and the degree of tumour
response to pre-operative RT is highly variable, even in patients
with the same clinical presentation at diagnosis. Some
patients may show a complete pathological response, whereby
no viable tumour remains in the specimen at the time of
surgery, whereas others will show no evidence of tumour
regression. Despite this variation in patient response, there are
currently no clinically approved, reliable methods to predict
individual patient response to pre-operative RT in rectal
cancer.
Additionally, although pre-operative RT has been shown to
reduce the risk of local recurrence, it is also associated with
significant adverse effects, and can increase the risk of long-
term morbidity following surgical resection.4–6 Adverse effects
from pre-operative RT vary depending on the individual
patient and the treatments received, but they range from mild
to severe and in some cases fatal. Acute toxicities commonly
experienced from RT include diarrhoea, nausea, stomatitis
and fatigue, and these symptoms typically persist throughout
the duration of the treatment. Long-term adverse effects
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induced by radiotherapy may include faecal incontinence,
bowel dysfunction, sexual dysfunction and an increased risk of
secondary malignancies, particularly within or surrounding
the irradiated volume.4,7–9
Although pre-operative RT aims to reduce the risk of local
recurrence and ultimately improve patient survival, a signifi-
cant proportion of patients endure the toxic side effects of RT
whilst showing no clinical benefit. In the case of some
patients, the adverse effects of pre-operative RT may outweigh
the potential benefit of receiving it. In addition to this, the
delivery of ineffective treatments places a financial burden on
the NHS and its finite resources. This highlights the impor-
tance of developing novel stratification techniques, and identi-
fying predictive biomarkers to facilitate personalised
medicine.
Raman spectroscopy (RS) is a rapid and highly sensitive
technique able to provide a unique molecular fingerprint of
cells and tissues through the varying contributions of mole-
cular bond vibrations.10–12 Advances in technology and analyti-
cal techniques over recent decades have rapidly broadened the
applications of RS.13,14 The potential uses of RS as a clinical
tool are well demonstrated in the literature and its ability to
detect subtle biochemical alterations in cells and tissues have
advanced its popularity as a desirable tool in cancer biology
and histopathology.10–17
The current CRC diagnostic pathway involves taking a
biopsy sample, tissue fixation, embedding in paraffin wax, sec-
tioning and staining, before analysis by a histopathologist. RS
has the potential to be easily implemented into this workflow.
It is a label-free, non-destructive technique that requires no
additional tissue preparation and can provide information-rich
spectra to aid histopathologists with the interpretation of stan-
dard morphology.10,18 However, the integration of RS in histo-
pathology laboratories at the present time is virtually non-exist-
ent. This is largely due to the widespread use of formalin-
fixed, paraffin-embedded (FFPE) tissue in standard clinical
practice. The spectrum of paraffin wax produces strong RS
peak intensities that fall within the fingerprint region and
have the potential to mask important biological tissue related
peaks.16,19
Deparaffinisation of FFPE tissue for RS analysis is impor-
tant, not only to remove the contaminating signals of the
paraffin wax the tissue has been embedded in, but also to
return the tissue as closely as possible to its in vivo state.
Although fresh tissue is ideal for RS analysis, as it avoids the
use of organic solvents that can greatly reduce the signal inten-
sity of the tissue and cause degradation and loss of some cellu-
lar components,24 it is not readily available outside of research
projects. FFPE tissue is integral to the routine clinical work-
flow, as it facilitates the production of optimal tissue sections
for diagnosis, and long-term preservation of material for sub-
sequent analysis.12 There is also an abundance of FFPE tissue
readily available in tissue archives or ‘bio-banks’, leading to
great potential for retrospective RS studies.
Here we report the development of RS as a tool to reliably
stratify response to pre-operative RT in rectal cancer patients,
using data collected from routine pre-treatment FFPE biopsy
specimens.
Methods
Case selection and assessment of response to pre-operative
radiotherapy
Anonymised FFPE tissue from a series of rectal cancer patients
treated with pre-operative SCRT was obtained from Leeds
Teaching Hospitals NHS Trust. Research ethics approval was pro-
vided by the North-East York Research Ethics Committee (ref. 08/
H0903/62). All patients in the series received the same 5 × 5 Gy
SCRT schedule, prior to surgical resection. Patient response to
pre-operative RT was assessed by quantifying the degree of
tumour regression following pre-operative RT. This was achieved
by calculating the percentage reduction in tumour cell density
(TCD) between the pre-treatment biopsy and the post-treatment
resection specimen. The cases were then categorised into ‘good’
and ‘poor’ responders, using the median percentage reduction in
TCD, 64.5%, as the threshold value to determine response.
TCD scoring was performed on digital scans of the original
haematoxylin and eosin (H&E) stained tissue sections, used for
diagnosis. The TCD scores were calculated as previously
described.25 Briefly, the H&E stained sections were scanned at
×20 magnification using an Aperio T3 scanner (Aperio
Technologies, Vista, California, USA). For each resection case,
the slide that showed the greatest tumour involvement was
selected for TCD scoring. To calculate the TCD of the biopsy,
the total area of tumour was annotated in ImageScope v12.3
(Aperio Technologies Inc., Vista, California, USA), avoiding any
normal tissue and areas of extensive necrosis. For each corres-
ponding resection, the total area of tumour, including any
tumour-associated stroma and any scar tissue, was annotated.
300 (±15) randomly assigned points were added to the tumour
annotation layers using RandomSpot v7.0.01 (University of
Leeds, Leeds, UK), which were then uploaded back onto the
digital slide. Manual scoring of the tissue component directly
beneath each point was performed according to a set of nine
histological criteria, as listed in Table 1. The TCD was then
Table 1 Tumour cell density (TCD) scores and corresponding patho-
logical criteria. The TCD is calculated as the percentage of viable
tumour cells (score 1) out of all of the informative points (scores 1–8).
Non-informative (score 0) applies to any point that is unable to be
classified
Score Criteria
0 Non-informative (unclassifiable)
1 Tumour cell
2 Stroma/collagen/fibrosis
3 Necrosis
4 Blood vessel
5 Inflammatory cells
6 Tumour lumen
7 Mucin
8 Muscle
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expressed as the proportion of tumour cells (score 1) out of all
informative points (scores 1–8). The percentage reduction in
TCD was calculated by comparing the TCD scores of the pre-
treatment biopsy and the corresponding post-treatment resec-
tion sample.
For this hypothesis generating study, 20 cases were selected
for Raman analysis. Cases were excluded if either the pre-treat-
ment biopsy or the post-treatment resection blocks were not
available, and from the remaining 62 cases, ten were selected
from each extreme of good and poor response to pre-operative
RT.
Preparation of samples for Raman analysis
Three serial sections cut at 8 μm were taken from the pre-treat-
ment biopsy tissue blocks for RS analysis. The first section was
stained with H&E and digitally scanned at ×20 magnification
(Aperio T3 scanner) in order to annotate the regions of interest
in ImageScope v12.3, for RS analysis. The entire tumour area
of the biopsy was annotated freehand and within this a 200 ×
200 μm grid annotated in the area of apparent greatest tumour
cell density, to denote the region for Raman analysis, as shown
in Fig. 1.
The second tissue section was mounted onto a fused quartz
microscope slide (Alfa Aesar, Massachusetts, USA) for RS ana-
lysis. Prior to tissue mounting, the quartz slides were prepared
by incubating overnight in 1% Decon, then sonicating in 1%
Decon, isopropyl alcohol and deionised H2O for 15 minutes
respectively, rinsing with deionised H2O in between each soni-
cation. The quartz slides were then silanised to encourage
tissue adhesion, by incubating for 15 seconds in a 4%
3-Aminopropyltriethoxysilane (APTES) in acetone solution, fol-
lowed by 15 seconds incubations in acetone and MilliQ
respectively.
Following tissue mounting, the samples were left overnight
at 37 °C, then baked on a hotplate at approximately 70 °C for
one hour prior to deparaffinisation to further encourage tissue
adhesion. The slides were taken through a series of five-
minute xylene and ethanol baths, to remove the wax and rehy-
drate the tissue.
Raman system configuration and data acquisition
The system used was an RA816 benchtop Raman Spectrometer
(Renishaw), fitted with a 785 nm diode laser, with a laser
power of 300 mW at the source and >150 mW at the sample,
and an integral plasma filter. Data were collected using an
8.2 mm working distance, 0.55 NA 50× long working distance
objective. Prior to experimental data collection, the system was
calibrated and aligned using internal silicon and neon
references.
Mapping measurements of 100 spectra, taken on a 10 × 10
array were collected over a 200 × 200 μm area from each biopsy
sample. Each spectrum was obtained using a one second
acquisition time and 15 accumulations, resulting in a total
laser acquisition time of 15 seconds at each point and total
mapping time of approximately 30 minutes. All data was col-
lected from the 715–2040 cm−1 spectral region.
Pre-processing and analysis of the spectra
The raw spectra were cosmic ray filtered, using a maximum
width of 3 cm−1 and threshold height of 10 counts, in WiRE
4.2 (Renishaw, Wotton-under-Edge, UK) to remove any cosmic
rays detected during mapping. All subsequent pre-processing
and data analysis were performed in MATLAB (MathWorks,
Massachusetts, USA). The wavenumber axis of each spectrum
was corrected to the corresponding silicon calibration peak
520.5 cm−1 and truncated to consider only the region between
Fig. 1 H&E stained tissue section of a biopsy specimen annotated for subsequent Raman analysis. (A) The entire tumour area of the biopsy speci-
men was first annotated, as shown by the continuous green line, before selecting a 200 × 200 μm tumour rich region to collect Raman measure-
ments from (green grid). The area highlighted by a black box is shown at higher magnification in (B). The grid shows the array of points at which the
100 spectra were obtained.
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850–1800 cm−1. The baseline was then removed using the
algorithm developed by Koch et al.26 Contaminating wax con-
tributions were subtracted from the data using a modified
extended multiplicative signal correction (EMSC) technique,
described by Ibrahim et al.18 Using this method, the inhomo-
geneous nature of the wax contributions are accounted for by
considering a matrix of 100 reference spectra of pure paraffin
mounted on quartz in the algorithm, instead of a single refer-
ence spectrum.
Poor quality biological spectra, or spectra taken from
regions lacking any biological tissue (such as those obtained
from the surrounding quartz substrate) were filtered from the
analysis, based on the presence and intensity of the phenyl-
alanine peak at approximately 1003 cm−1. The threshold ratio
of the phenylalanine peak area (integrated from
998–1010 cm−1) to the adjacent spectral regions
(983–985 cm−1) was set at 15 for all spectra. Any spectra that
did not meet this threshold ratio were discounted from the
analysis.
Principal component analysis (PCA) was performed using
the pca function in MATLAB. The data was standardised using
a standard normal variate (SNV) method within the pca func-
tion. Following this, the fitcdiscr function (‘linear’ discriminant
type) was used for linear discriminant analysis (LDA). All
spectra collected from the Raman maps taken from good and
poor responders were combined in their respective group, and
randomly split for five-fold cross validation, to estimate the
performance of the model. This process was repeated 100
times and the output from each validation set was used to cal-
culate the average sensitivity, specificity and accuracy of the
model.
Results
Cases selected for Raman analysis
From the 20 cases analysed, those showing a poor response to
pre-operative RT had a median percentage reduction in TCD of
−2.5% (IQR −29.4–7.9%), and those that showed a good
response had a median percentage reduction in TCD of 94.7%
(IQR 90.6–97.9%). The median patient age was 64 years at the
time of surgery (IQR = 56–74 years), and the sample population
contained 13 male, and 7 female patients. A summary of the
clinicopathological data, including tumour, node, metastasis
(TNM) stage and tumour differentiation grade, of the patients
in this study is summarised in Table 2.
Pre-processed Raman spectra
The raw Raman spectra contained contaminating paraffin
peaks, which were observed at varying intensities at the follow-
ing positions; 1063 cm−1, 1133 cm−1, 1296 cm−1, 1418 cm−1,
1441 cm−1 and 1464 cm−1, representative of the distinctive C–
C stretching and CH2 and CH3 deformation.
20 Fig. 2 shows an
example spectrum during the pre-processing stage, whereby
the ‘raw’ truncated spectrum (blue) is corrected to reduce the
paraffin contributions (green), to the level of the background
noise (orange). Standard deparaffinisation protocols typically
employed in histopathology laboratories involve the use of a
clearing agent followed by rehydration of the tissue. Faoláin
Table 2 Clinicopathological data summary of the 20 cases. The TNM
staging system, as described by the AJCC, is used to stage colorectal
tumours.27 T relates to the primary tumour, N refers to the extent of
metastatic disease in the lymph nodes and M refers to the extent of
distant metastatic disease. The 5th version of TNM staging was used
Number of cases
Good responders Poor responders
Sex of Patient
Male 8 5
Female 2 5
Patient age (years)
Median (IQR) 66 (60–72) 60 (55–75)
Percentage reduction in tumour cell density (%)
Median (IQR) 94.7 (90.6–97.9) −2.5 (−29.4–7.9)
ypT stage
pT1 1 1
pT2 6 1
pT3 3 8
ypN stage
pN0 10 6
pN1 0 4
ypM stage
pM0 0 0
pM1 1 0
pMx 9 10
Differentiation grade
Well 0 1
Moderate 9 8
Poor 0 1
Unknown 1 0
Fig. 2 Digital paraffin removal using EMSC. Residual paraffin peaks, follow-
ing ‘de-waxing’ are shown in the example spectra (blue) with major bands
indicated by the dashed lines at 1062 cm−1, 1133 cm−1, 1296 cm−1,
1418 cm−1, 1441 cm−1 and 1464 cm−1. The pre-processed spectra (orange)
shows the reduction of paraffin contributions, following EMSC and baseline
correction. The average paraffin spectrum, obtained from 100 point
measurements of pure paraffin, is shown in green for reference (the intensity
of the paraffin spectrum has been reduced four-fold to aid visualisation).
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et al. originally reported the use of RS to detect the presence of
paraffin wax in FFPE tissues following deparaffinisation using
several common chemical dewaxing agents.20 Inefficient
paraffin removal by commonly used deparaffinisation proto-
cols, has been reported in both the RS and infrared spec-
troscopy communities.19–21 However, alongside the standard
chemical deparaffinisation agents, computational methods
have also been employed to remove contaminating paraffin
peaks from the Raman spectra of biological tissue. There are
several approaches to digital subtraction from Raman spectra
that have been used to remove residual wax contributions and
the background signal of substrates.18,22,23 Most recently,
Ibrahim et al. reported efficient paraffin signal removal using
an EMSC algorithm that employs a matrix of paraffin wax
spectra as a reference, to account for the heterogeneity of
paraffin.18 Using this technique, we were able to eliminate the
contaminating residual paraffin peaks in the spectra.
For the biopsy specimens, 2000 spectra were collected in
total: 100 spectra from each of the 20 samples. However, 123
poor quality spectra that did not achieve the threshold ratio of
phenylalanine peak intensity were filtered and removed from
subsequent analysis. This resulted in a total of 1877 spectra:
1055 good response spectra, and 822 poor response spectra.
The average Raman spectrum of patients who showed a
good response to pre-operative RT, and that of those who
showed a poor response to pre-operative RT, are compared in
Fig. 3. Notable Raman peaks characteristic of biological tissue,
including peaks corresponding to the ring breathing mode of
amino acid phenylalanine (1004 cm−1), the C–N stretch and
N–H bend of Amide III (1230–1300 cm−1), the CH2 defor-
mation of proteins and lipids (1450 cm−1), and the CvO
stretch of Amide I (1665 cm−1) were observed in our results.
Fig. 3 shows these peaks, in addition to other biological peaks
and their tentative assignments, which were allocated using
references from the current literature.14,15,28
The Raman spectra of biological tissue are inherently
complex in nature, due to overlapping peaks from the vast
number of tissue components within the sample.14 Subtle
differences between good and poor responders were observed
in the relative peak intensities and bandwidths of Raman
peaks associated with protein and lipid contributions across
the spectrum. The average spectrum of good responders
showed a greater Raman intensity of peaks associated with
protein contributions; 1004 cm−1 (phenylalanine), 1235 cm−1
and 1250 cm−1 (fitted to the β-sheet and disordered structure
peaks of Amide III, respectively) and 1665 cm−1 (Amide I).
Whereas, the average spectrum of poor responders showed
increased lipid contributions; 1315–1340 cm−1 (CH2CH3 defor-
mation) and 1450 cm−1 (CH2 deformation).
Multivariate analysis: PCA and LDA
Fig. 4A shows the loadings of the first three principal com-
ponents (PCs) that were responsible for approximately 97% of
the total variance. Multivariate statistical techniques, PCA and
LDA, were employed to detect subtle features that differentiate
the Raman spectra of good and poor responders. PCA is an
unsupervised form of multivariate analysis, that reduces the
dimensionality of the data, by linear transformation of the
original variables into PCs.29,30 The first two PCs, PC1 and
PC2, accounted for the most variance (95.2%), with PC2 being
the most discriminatory component. Both PC1 and PC2 show
contributions from peaks commonly associated with biological
Fig. 3 Averaged spectra obtained from biopsy specimens of good and poor response groups, shown in blue and orange respectively. Tentative
peak assignments of the main spectral bands are annotated.
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tissue; a phenylalanine peak at approximately 1004 cm−1, CH2
deformations typically associated with lipids at approximately
1450 cm−1 and Amide I signal at around 1669 cm−1. PC2 also
showed additional notable peaks around 1115 cm−1 and
1239 cm−1, corresponding to lipid and Amide III contributions
respectively, and an additional phenylalanine peak at
1033 cm−1. PC3 was dominated by peaks observed from the
quartz substrate the tissue was mounted on. These include the
broad peaks centred around approximately 1055 cm−1 and
1190 cm−1. PC3 showed additional biological peaks, including
Amide I signal at approximately 1669 cm−1, and C–C defor-
mation of lipids/C–N deformation of proteins at around
1133 cm−1.
Fig. 4B shows a clear separation of good and poor respon-
ders was achieved by plotting the PC1 versus PC2 scores of
each point in the 10 × 10 array for all samples. The scores for
PC1 – 3, from good and poor responders are shown in Fig. 4C.
The first eight PCs (responsible for >98% of the total var-
iance) were input into the LDA, a supervised technique that
maximises the between-class variance, creating a linear bound-
ary between classes.29–31 Classification of good and poor
response was achieved with an accuracy of 86.04 ± 0.14% (stan-
dard error), 84.20 ± 0.27% sensitivity and 81.01 ± 0.37% speci-
ficity. Generally, positive LDA scores corresponded to Raman
spectra taken from a sample that showed a good response to
pre-operative RT, whereas negative scores corresponded to
those that showed a poor response to pre-operative RT, as illus-
trated in Fig. 5A.
Fig. 5B shows the loading plot of the linear discriminant
(LD) that achieved the best classification of response. The posi-
tive loading intensities were dominated by peaks that are typi-
cally associated with proteins and amino acids. These included
peaks at 1168 cm−1 (C–H bending of tyrosine), 880 cm−1 and
1365 cm−1 (tryptophan), 1220 cm−1 (β sheet Amide III) and
1461 cm−1 (CH2 deformation of proteins/lipids). Peaks corres-
ponding to nucleic acids, 1487 cm−1 (guanine/adenine) and
1582 cm−1 (pyrimidine ring of cytosine and thymine), also
showed positive contributions to the LD loading.
In contrast, negative contributions to the LD were predomi-
nantly attributed to peaks mostly associated with lipid contri-
Fig. 4 Results of PCA. (A) Plotted shapes of PC1 – PC3. (B) 2D scatter plot of PC1 and PC2 scores. (C) Scatter plot/box plot showing the scores of
good responders and poor responders for PC 1–3. Each point represents a single Raman spectrum acquired from the Raman map measurements of
the 20 biopsy samples.
Paper Analyst
Analyst This journal is © The Royal Society of Chemistry 2020
O
pe
n 
A
cc
es
s 
A
rt
ic
le
. P
ub
lis
he
d 
on
 1
0 
N
ov
em
be
r 
20
20
. D
ow
nl
oa
de
d 
on
 1
1/
13
/2
02
0 
4:
49
:5
4 
PM
. 
 T
hi
s 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
C
om
m
on
s 
A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
L
ic
en
ce
.
View Article Online
butions. These peaks include those at 1133 cm−1 (C–C of
lipids/C–N proteins), 1348 cm−1 (CH2CH3 deformation of col-
lagen/lipids) and 1450 cm−1 (CH2 deformation). Other peaks
that contributed to the negative score were 1274 cm−1 and
946 cm−1, which are associated with the α helix of Amide III
and proline, valine and glycogen respectively.
We note that the LDA also showed a shift in the phenyl-
alanine peak position between good and poor response
groups, from 1000 to 1006 cm−1. Although this falls within the
expected range of the phenylalanine peak, we presume that
the shift is indicative of the different protein composition
within the tissue of good and poor responders.
The results of the LDA confirmed the elevated lipid content
observed in the average spectra obtained from the biopsies of
patients who responded poorly to pre-operative RT (Fig. 3).
Interestingly, these findings are in accordance with previously
reported research, linking chemoresistance of several cancers,
including CRC, to the dysregulation of lipid metabolism and
the accumulation of lipid droplets (LDs).32,33 Additionally, a
RS study by Tirinato et al. determined that increased levels of
lipid droplets are characteristic of cancer stem cells in CRC,
which are thought to have increased resistance to
chemotherapies.34,35
Whilst our results show promising similarities with trends
seen in the chemoresistance of CRC, we acknowledge that
additional work is required to confirm these findings. This
study considers only RS data collected from rectal cancer
patients at the extremes of response, and does not consider
those who showed a ‘moderate’ response to pre-operative RT.
We hypothesise that these patients would show a combination
of good and poor response signals, and therefore would
require additional interpretation and consideration by a clini-
cian. However, the intention is not that RS could replace the
role of a clinician in CRC care, but provide additional infor-
mation to guide patient treatment. In addition, these results
only consider response to pre-operative SCRT, however, rectal
cancer patients may also receive LCCRT. Further work would
include validation of the model on a cohort of LCCRT patients
and additional analysis of the corresponding post-treatment
resection specimens to elucidate the molecular mechanisms of
patient response.
Furthermore, the entirety of the sample population used in
this study received treatment at the same hospital and there-
fore were subjected to the same tissue processing and embed-
ding protocols. Although the general processes are standar-
dised, there is likely to be slight variation in protocols across
different hospital trusts and therefore the model should also
be validated using samples from other hospitals.
Conclusions
This study has demonstrated subtle differences in the Raman
spectra obtained from routine FFPE biopsy samples of rectal
cancer patients who responded well to pre-operative RT and
showed significant tumour regression, when compared to
those who responded poorly. The Raman signature of patients
that showed a good response showed increased protein contri-
butions, whereas poor responders showed elevated lipid con-
tributions. These differences were confirmed using a PCA-LDA
algorithm, which was able to classify patient response to pre-
operative RT into ‘good’ or ‘poor’ with an accuracy of approxi-
mately 86%, based on the spectra obtained from the pre-treat-
ment biopsy samples. Although not absolute, this study has
demonstrated that RS is able to detect subtle changes in the
biochemical fingerprint of patient biopsy specimens, to stratify
patient response to pre-operative RT, with a sufficient level of
accuracy. Furthermore, this highlights the potential to develop
RS as a tool to predict patient response to pre-operative
therapy, to ultimately aid a clinician and guide personalised
patient treatment in rectal cancer.
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